WYC-209
Names
[ CAS No. ]:
2131803-90-0
[ Name ]:
WYC-209
Biological Activity
[Description]:
WYC-209, a synthetic retinoid, inhibits proliferation of malignant murine melanoma tumor-repopulating cells (TRCs) with an IC50 of 0.19 μM, has long-term effects and little toxicity, and induces TRCs apoptosis primarily via the caspase 3 pathway. The primary cellular target of WYC-209 is retinoic acid receptor (RAR)[1].
[Related Catalog]:
[Target]
Retinoic acid receptor[1]
[In Vitro]
WYC-209 (10 μM; 24 hours) is able to inhibit and block growth of TRCs of human tumor cells in culture with a long-lasting effect[1]. Apoptosis Analysis[1] Cell Line: A2780, A549, MCF-7, MDA-MB-435s, A375 cells Concentration: 10 μM Incubation Time: 24 hours Result: TRCs failed to resume growth 5 days after the drug washout.
[In Vivo]
WYC-209 (0.022-0.22 mg/kg; i.v.; once every two days for 25 days) inhibits tumor metastasis in C57BL/6 mice bearing lung metastases[1]. Animal Model: Female immune-competent C57BL/6 mice[1] Dosage: 0.022, 0.22 mg/kg Administration: Intravenous injection; once every two days for 25 days Result: Four out of eight mice formed lung metastases at dose of 0.022 mg /kg, only one out of eight mice formed lung metastases at dose of 0.22 mg/kg.
[References]
Chemical & Physical Properties
[ Molecular Formula ]:
C20H20N2O3S
[ Molecular Weight ]:
368.45
[ Storage condition ]:
2-8℃